Quang X. Pham's Planned Sale of Common Stock in Cadrenal Therapeutics, Inc.

Quang X. Pham, an officer of Cadrenal Therapeutics, Inc., has filed a notice of planned sale of 1,315 shares of common stock, acquired as Founders Shares on January 25, 2022. The sale is scheduled for October 27, 2025, with an aggregate market value of $18,396.86. Additionally, Pham has engaged in multiple transactions over the past three months, selling a total of 19,129 shares for gross proceeds of $283,584.86. These transactions were executed through Merrill Lynch, with the shares traded on NASDAQ. The filing highlights Pham's ongoing divestment of his holdings in the company.